29 research outputs found
Simultaneous occurrence of cerebellar medulloblastoma and pituitary adenoma: A case report
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licens
Is there any potential link among caspase-8, p-p38 MAPK and bcl-2 in clear cell renal cell carcinomas? A comparative immunohistochemical analysis with clinical connotations
Abstract Background Clear cell renal cell carcinomas (ccRCCs) constitute the most common renal carcinomas, characterized by a relatively aggressive clinical course. Thus, scientific research is targeting towards the identification of immunohistochemical and molecular markers that could be useful regarding diagnosis, appropriate therapy and prediction of prognosis. In the present study we assessed and correlated the expression of caspase-8, phosphorylated p38 mitogen-activated protein kinase (p-p38) and bcl-2 protein with histopathological features and clinical outcome of 27 patients with ccRCCs. Method Immunohistochemistry in formalin-fixed and paraffin-embedded tissue sections was performed. The associations among various features were assessed utilizing statistical analysis. Results We found that increased expression of cytoplasmic caspase-8 and bcl-2 protein was strongly associated with low Fuhrman's grade of carcinomas (p = 0.019 and p = 0.041, respectively). On the other hand, increased p-p38 expression was significantly related to high Fuhrman's grade (p = 0.006). Moreover, high bcl-2 expression was correlated with low pathological stage of ccRCCs (p = 0.026). Increased expression of cytoplasmic caspase-8 as well as low-grade tumors (grade 1 and 2) implied a greater probability of patients' survival, in univariate statistical analysis (p = 0.037 and p = 0.019, respectively). Neither p-p38 nor bcl-2 expression was significantly linked to patients' survival. There were not emerged statistically significant associations among caspase-8, p-p38 kinase and bcl-2 protein. Conclusion For the first time the prognostic impact of caspase-8 and p-p38 was studied in a series of ccRCCs, using immunohistochemistry in formalin-fixed and paraffin-embedded tissue sections. The suggestive relationship of caspase-8 with patients' clinical outcome, as well as the role of p-p38 within different grade categories, mandates further studies in larger cohorts of RCCs.</p
Is there any potential link among caspase-8, p-p38 MAPK and bcl-2 in clear cell renal cell carcinomas? A comparative immunohistochemical analysis with clinical connotations
10.1186/1746-1596-4-7Diagnostic Pathology41
Is there any potential link among caspase-8, p-p38 MAPK and bcl-2 in clear cell renal cell carcinomas? A comparative immunohistochemical analysis with clinical connotations
Background: Clear cell renal cell carcinomas (ccRCCs) constitute the
most common renal carcinomas, characterized by a relatively aggressive
clinical course. Thus, scientific research is targeting towards the
identification of immunohistochemical and molecular markers that could
be useful regarding diagnosis, appropriate therapy and prediction of
prognosis. In the present study we assessed and correlated the
expression of caspase-8, phosphorylated p38 mitogen-activated protein
kinase (p-p38) and bcl-2 protein with histopathological features and
clinical outcome of 27 patients with ccRCCs.
Method: Immunohistochemistry in formalin-fixed and paraffin-embedded
tissue sections was performed. The associations among various features
were assessed utilizing statistical analysis.
Results: We found that increased expression of cytoplasmic caspase-8 and
bcl-2 protein was strongly associated with low Fuhrman’s grade of
carcinomas (p = 0.019 and p = 0.041, respectively). On the other hand,
increased p-p38 expression was significantly related to high Fuhrman’s
grade (p = 0.006). Moreover, high bcl-2 expression was correlated with
low pathological stage of ccRCCs (p = 0.026). Increased expression of
cytoplasmic caspase-8 as well as low-grade tumors (grade 1 and 2)
implied a greater probability of patients’ survival, in univariate
statistical analysis (p = 0.037 and p = 0.019, respectively). Neither
p-p38 nor bcl-2 expression was significantly linked to patients’
survival. There were not emerged statistically significant associations
among caspase-8, p-p38 kinase and bcl-2 protein.
Conclusion: For the first time the prognostic impact of caspase-8 and
p-p38 was studied in a series of ccRCCs, using immunohistochemistry in
formalin-fixed and paraffin-embedded tissue sections. The suggestive
relationship of caspase-8 with patients’ clinical outcome, as well as
the role of p-p38 within different grade categories, mandates further
studies in larger cohorts of RCCs
Analysis of interleukin (IL)-8 expression in human astrocytomas: Associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry
Malignant astrocytomas are highly vascular neoplasms with potent angiogenic activity. The present study aimed to investigate peripheral and local expression of interleukin (IL)-8 in astrocytomas with possible associations to IL-6, cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF) expression, and microvessel morphometry. IL-6- and IL-8-secreting peripheral blood monocytes (PBMCs) were evaluated in 17 glioblastoma (WHO grade IV), 5 anaplastic astrocytoma (WHO grade III), and 6 diffuse astrocytoma patients (WHO grade II), in parallel with 23 healthy controls using enzyme-linked immunosorbent spot (ELISPOT) assay. The IL-8 expression was assessed immunohistochemically in patients' tumor tissue sections and correlated with the expression of COX-2, VEGF, IL-6, and microvessel morphometry (assessed using CD34 antibody). Eighteen cases were also stained for CD31 and used as an additional vessel marker to validate our results regarding microvessel morphometry. IL-6 and IL-8 were highly secreted in the PBMCs of glioma patients compared with controls (p = 0.0001, p < 0.0001, respectively), with a positive correlation between IL-8 expression and secretion levels (p = 0.001). IL-8 immunoreactivity was detected in malignant cells or macrophages in perivascular areas and in pseudopalisading cells around necrosis and was positively correlated with histological grade (p = 0.0175) and tumor necrosis (p = 0.0793). IL-6 and IL-8 expression levels were positively correlated (p = 0.0036) and associated with COX-2 and VEGF expression (IL-6: p = 0.0133, p = 0.065; IL-8: p = 0.0139, p = 0.0101), but not with microvessel morphometry, by either CD31 or CD34. The coordinate expression and topographical relationship of IL-6, IL-8, COX-2, and VEGF in the same tumor areas (e.g., perinecrotic areas) attest to their intimate liaison in terms of cancer-induced angiogenesis, which is probably secondary to the induction of multiple interdependent molecular pathways. Moreover, our study seems to be the first attempt to link IL-8 expression by tumor cells with histological grade, implicating its potent role in gliomagenesis
Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors
Glioblastoma, (grade IV astrocytoma), is characterized by rapid growth
and resistance to treatment. Identification of markers of aggressiveness
in this tumor could represent new therapeutic targets. Interleukins
(IL)-6 and IL-10 may be considered as possible candidates, regulating
cell growth, resistance to chemotherapy and angiogenesis. ELISPOT method
provides a useful tool for the determination of the exact cell number of
peripheral lymphocytes secreting a specific cytokine. IL-6 and IL-10
secretion levels were determined using ELISPOT methodology in peripheral
blood mononuclear cells of 18 patients with astrocytic neoplasms (3
grade II and 15 grade IV), in parallel with 18 healthy controls.
Additionally, immunohistochemical expression of these two cytokines was
performed in paraffin-embedded neoplastic tissue in 12 of these
patients. The secretion of IL-6 from peripheral monocytes was
significantly higher in glioma patients compared to controls (P =
0.0003). In addition, IL-10 secretion from peripheral mononuclear and
tumor cells of glioma patients was also higher as compared to healthy
controls (P = 0.0002). Based on immunohistochemical staining, IL-6
expression was localized in tumor cells and macrophages as well as in
areas of large ischemic necrosis, while the major source of IL-10
expression in glioblastomas was the microglia/macrophage cells. It is
suggested that IL-10 contributes to the progression of astrocytomas by
suppressing the patient’s immune response, whereas IL-6 provides an
additional growth advantage. This study demonstrates for the first time
the usefulness of ELISPOT in estimating the secretion of IL-6 and IL-10
from peripheral blood and the correlation of their expression in
neoplastic cells
Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas
International audienceKorkolopoulou P, Levidou G, El-Habr E A, Piperi C, Adamopoulos C, Samaras V, Boviatsis E, Thymara I, Trigka E-A, Sakellariou S, Kavantzas N, Patsouris E & Saetta A A ?(2012) Histopathology similar to 61, 293305 Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas Aims: To investigate the significance of the mammalian target of rapamycin (mTOR) pathway in astrocytic tumours, published information in this context being limited, especially regarding phosphorylated 4E-binding protein (p-4E-BP) 1. Methods and results: Paraffin-embedded tissue from 111 patients with astroglial tumours (grades IIIV) was investigated for the association of phosphorylated mTOR (p-mTOR) signalling components with phosphorylated extracellular signal-related kinase 1/2 (p-ERK1/2) and phosphorylated AKT (p-AKT) expression, clinicopathological features, angiogenesis, isocitrate dehydrogenase 1 (IDH1)-R132H, and survival. Expression was also quantified by western blot analysis in 12 cases and in three primary glioma cell cultures following rapamycin treatment. p-mTOR expression correlated with p-4E-BP1 expression and marginally with p-p70S6K expression. p-4E-BP1 expression increased with tumour grade. Rapamycin induced a decline in phosphorylation levels of all three proteins. Nuclear p-AKT and cytoplasmic p-ERK1/2 immunoexpression correlated with p-4E-BP1 expression, whereas cytoplasmic p-AKT expression correlated with p-p70S6K expression. All three proteins were associated with increased angiogenesis but not with IDH1-R132H expression status. p-mTOR adversely affected overall and disease-free survival in univariate analysis. In multivariate survival analysis, the presence of p-4E-BP1 predicted shortened overall survival in the entire cohort and glioblastomas. Conclusions: mTOR signalling components are differentially involved in the acquisition of a more aggressive and angiogenic phenotype in astrocytic tumours. Moreover, p-4E-BP1 emerges as a novel prognostic marker, which might aid in the selection of patients who are more likely to benefit from therapy with mTOR inhibitors
Expression of Interleukin-8 Receptor CXCR2 and Suppressor of Cytokine Signaling-3 in Astrocytic Tumors
The aim was to expand recently published information regarding the
significance of the interleukin (IL)-8/p-STAT-3 (signal transducer and
activator of transcription) pathway in astrocytomas, focusing on the
IL-8 receptor, chemokine (C-X-C motif) receptor 2 (CXCR2), and the
STAT-3 inhibitor SOCS-3 (suppressors of cytokine signaling). A total of
91 paraffin-embedded human astrocytoma tissues (grades II-IV) were
investigated for the association of SOCS-3 and CXCR2 expression with
clinicopathologic and morphometric microvascular characteristics,
vascular endothelial growth factor (VEGF), IL-8 and p-STAT-3 expression
and patient survival. Peripheral IL-8 secretion levels were assessed by
enzyme-linked immunosorbent spot (ELISPOT). SOCS-3, p-STAT-3 and CXCR2
protein levels were also quantified by Western immunoblotting in six
cases, and the protein levels of SOCS-3 and CXCR2 were correlated with
the immunohistochemical expression of the respective proteins. All
CXCR2-positive cases by Western immunoblotting displayed increased
peripheral IL-8 secretion levels. Treatment of primary glioblastoma cell
cultures with exogenous IL-8 enhanced proliferation, and this effect was
inhibited by treatment with a neutralizing anti-CXCR2 antibody. SOCS-3
and CXCR2 were expressed by neoplastic astrocytes in 92.4% and 48.78%
of cases, respectively, with their levels increasing with histological
grade and extent of necrosis. VEGF expression and microvessel density,
CXCR2 and IL-8 levels were interrelated, SOCS-3 and p-STAT-3 were
co-expressed in 85.7% of cases, although they were not interrelated. In
univariate survival analysis, increased SOCS-3 expression and the
presence of CXCR2 adversely affected survival, whereas in multivariate
analysis, only CXCR2 remained significant. The prognostic significance
of CXCR2 was validated in an independent set of 63 patients. Our data
implicate IL-8/CXCR2 signaling pathway in the progression and regulation
of angiogenesis in astrocytomas and provide a rationale for CXCR2
therapeutic exploitation in these tumors. Online address:
http://www.molmed.org doi: 10.2119/molmed.2011.0044
Emerging role of linker histone variant H1x as a biomarker with prognostic value in astrocytic gliomas. A multivariate analysis including trimethylation of H3K9 and H4K20.
Although epigenetic alterations play an essential role in gliomagenesis, the relevance of aberrant histone modifications and the respective enzymes has not been clarified. Experimental data implicates histone H3 lysine (K) methyltransferases SETDB1 and SUV39H1 into glioma pathobiology, whereas linker histone variant H1.0 and H4K20me3 reportedly affect prognosis. We investigated the expression of H3K9me3 and its methyltransferases along with H4K20me3 and H1x in 101 astrocytic tumors with regard to clinicopathological characteristics and survival. The effect of SUV39H1 inhibition by chaetocin on the proliferation, colony formation and migration of T98G cells was also examined. SETDB1 and cytoplasmic SUV39H1 levels increased from normal brain through low-grade to high-grade tumors, nuclear SUV39H1 correlating inversely with grade. H3K9me3 immunoreactivity was higher in normal brain showing no association with grade, whereas H1x and H4K20me3 expression was higher in grade 2 than in normal brain or high grades. These expression patterns of H1x, H4K20me3 and H3K9me3 were verified by Western immunoblotting. Chaetocin treatment significantly reduced proliferation, clonogenic potential and migratory ability of T98G cells. H1x was an independent favorable prognosticator in glioblastomas, this effect being validated in an independent set of 66 patients. Diminished nuclear SUV39H1 expression adversely affected survival in univariate analysis. In conclusion, H4K20me3 and H3K9 methyltransferases are differentially implicated in astroglial tumor progression. Deregulation of H1x emerges as a prognostic biomarker
Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development
International audienceWe investigated the significance of PI3K/AKT/mTOR pathway and its interactions with MAPK, JAK/STAT and Notch pathways in meningioma progression. Paraffin-embedded tissue from 108 meningioma patients was analysed for the presence of mutations in PIK3CA and AKT1. These were correlated with the expression status of components of the PI3K/AKT/mTOR pathway, including p85 alpha and p110 gamma subunits of PI3K, phosphorylated (p)-AKT, p-mTOR, p-p70S6K and p-4E-BP1, as well as of p-ERK1/2, p-STAT3 and Notch-1, clinicopathological data and patient survival. A mutation in PIK3CA or AKT1 was found in around 9 % of the cases. Higher grade meningiomas displayed higher nuclear expression of p-p70S6K; higher nuclear and cytoplasmic expression of p-4E-BP1 and of Notch-1; lower cytoplasmic expression of p85 alpha PI3K, p-p70S6K and p-ERK1/2; and lower PTEN Histo-scores (H-scores). PTEN H-score was inversely correlated with recurrence probability. In univariate survival analysis, nuclear expression of p-4E-BP1 and absence of p-ERK1/2 expression portended adverse prognosis, whereas in multivariate survival analysis, p-ERK1/2 expression emerged as an independent favourable prognostic factor. Treatment of the human meningioma cell line HBL-52 with the PI3K inhibitor LY294002 resulted in reduction of p-AKT, p-p70S6K and p-ERK1/2 protein levels. The complex interactions established between components of the PI3K/AKT/mTOR pathway, or with components of the MAPK, JAK/STAT and Notch-1 pathways, appear to be essential for facilitating and fuelling meningioma progression